Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
ALXN-2220 by Alexion Pharmaceuticals for Familial Amyloid Cardiomyopathy: Likelihood of Approval
ALXN-2220 is under clinical development by Alexion Pharmaceuticals and currently in Phase I for Familial Amyloid Cardiomyopathy. According to GlobalData,...
Data Insights
ALXN-2220 by Alexion Pharmaceuticals for Amyloid Cardiomyopathy: Likelihood of Approval
ALXN-2220 is under clinical development by Alexion Pharmaceuticals and currently in Phase III for Amyloid Cardiomyopathy. According to GlobalData, Phase...